EDIT
Price
$2.53
Change
-$0.03 (-1.17%)
Updated
Dec 12 closing price
Capitalization
246.98M
68 days until earnings call
Intraday BUY SELL Signals
RXRX
Price
$4.33
Change
-$0.25 (-5.46%)
Updated
Dec 12 closing price
Capitalization
2.25B
81 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs RXRX

Header iconEDIT vs RXRX Comparison
Open Charts EDIT vs RXRXBanner chart's image
Editas Medicine
Price$2.53
Change-$0.03 (-1.17%)
Volume$2.27M
Capitalization246.98M
Recursion Pharmaceuticals
Price$4.33
Change-$0.25 (-5.46%)
Volume$17.98M
Capitalization2.25B
EDIT vs RXRX Comparison Chart in %
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 58 to 114.69B. VRTX holds the highest valuation in this group at 114.69B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 65%. NBY experienced the highest price growth at 158%, while BPTSY experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -11%. For the same stocks of the Industry, the average monthly volume growth was -7% and the average quarterly volume growth was 72%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 80
Price Growth Rating: 54
SMR Rating: 92
Profit Risk Rating: 93
Seasonality Score: 17 (-100 ... +100)

Market Cap

The average market capitalization across the group is 1.32B. The market cap for tickers in the group ranges from 249.9M to 2.38B. RXRX holds the highest valuation in this group at 2.38B. The lowest valued company is EDIT at 249.9M.

High and low price notable news

The average weekly price growth across all stocks in the group was -1%. For the same group, the average monthly price growth was -3%, and the average quarterly price growth was 12%. EDIT experienced the highest price growth at 5%, while RXRX experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the group was 2%. For the same stocks of the group, the average monthly volume growth was -12% and the average quarterly volume growth was -47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 44
P/E Growth Rating: 100
Price Growth Rating: 53
SMR Rating: 98
Profit Risk Rating: 100
Seasonality Score: -50 (-100 ... +100)
VS
EDIT vs. RXRX commentary
Dec 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and RXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 14, 2025
Stock price -- (EDIT: $2.56 vs. RXRX: $4.58)
Brand notoriety: EDIT and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 93% vs. RXRX: 30%
Market capitalization -- EDIT: $246.98M vs. RXRX: $2.25B
EDIT [@Biotechnology] is valued at $246.98M. RXRX’s [@Biotechnology] market capitalization is $2.25B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, both EDIT and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • EDIT’s TA Score: 5 bullish, 4 bearish.
  • RXRX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than RXRX.

Price Growth

EDIT (@Biotechnology) experienced а +5.35% price change this week, while RXRX (@Biotechnology) price change was -6.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.68%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +64.61%.

Reported Earning Dates

EDIT is expected to report earnings on Feb 19, 2026.

RXRX is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.25B) has a higher market cap than EDIT($247M). EDIT YTD gains are higher at: 101.575 vs. RXRX (-32.249). EDIT has higher annual earnings (EBITDA): -189.17M vs. RXRX (-636.09M). RXRX has more cash in the bank: 660M vs. EDIT (166M). EDIT has less debt than RXRX: EDIT (19.7M) vs RXRX (82.4M). EDIT has higher revenues than RXRX: EDIT (46.4M) vs RXRX (43.4M).
EDITRXRXEDIT / RXRX
Capitalization247M2.25B11%
EBITDA-189.17M-636.09M30%
Gain YTD101.575-32.249-315%
P/E RatioN/AN/A-
Revenue46.4M43.4M107%
Total Cash166M660M25%
Total Debt19.7M82.4M24%
FUNDAMENTALS RATINGS
EDIT: Fundamental Ratings
EDIT
OUTLOOK RATING
1..100
14
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
47
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
EDITRXRX
RSI
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 10 days ago
84%
Declines
ODDS (%)
Bearish Trend 23 days ago
89%
Bearish Trend 24 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
EDIT
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MVCKX31.950.28
+0.88%
MFS Mid Cap Value R6
CAMSX18.190.12
+0.66%
Cambiar Small Cap Inv
MWOHX65.780.36
+0.55%
MFS Global Growth R3
CBHIX8.68-0.03
-0.34%
Victory Market Neutral Income I
TFCCX20.12-0.30
-1.47%
Touchstone Large Cap C

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been closely correlated with CRSP. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-3.98%
CRSP - RXRX
69%
Closely correlated
+0.87%
ABSI - RXRX
62%
Loosely correlated
-3.27%
BEAM - RXRX
61%
Loosely correlated
+0.40%
ABCL - RXRX
58%
Loosely correlated
-0.80%
RGNX - RXRX
54%
Loosely correlated
-1.61%
More